Overall immune reconstitution in patients infused with iC9-T cells. Counts of circulating CD3⁺CD19⁺ (A) and CD3⁺CD19⁻ T cells (B). Shaded area indicates counts of circulating CD3⁺ T cells in 4 control patients who underwent haplo-HSCT without T-cell add-back, and time point 0 that corresponds to month 3 posttransplant. Subset composition of circulating CD3⁺CD19⁺ (C) and CD3⁺CD19⁻ T cells (D). Counts of circulating natural killer cells (E) and B lymphocytes (F). The number of evaluable patients at each points is 10 (month 1), 9 (months 2 and 3), 8 (months 4, 6, and 9), 7 (month 12), and 4 (month 24). Data show means ± standard error of mean of the patients infused with iC9-T cells.